User login
BOSTON — Statin therapy was associated with a significantly reduced risk for Candida colonization or infection in patients with type 2 diabetes who were undergoing gastrointestinal tract surgery.
Of the total 1,019 patients who underwent the surgery between January 1, 2001 and May 1, 2008, 48% (493) received statin therapy and 52% (526) did not. Those with statin exposure were older (67.8 vs. 64.9 years, respectively), and had a higher modified Charleson comorbidity index, Dr. Ilias Spanakis said.
A total of 139 patients developed Candida colonization or infection. After adjustment for major confounders, statin use was associated with a statistically significant 40% reduction in the development of Candida colonization or infection (odds ratio, 0.60).
Statins were associated with reduced risk of Candida colonization or infection regardless of Charleson score, although there was a greater apparent benefit of statins in those with scores of 2 or higher, indicating more comorbidity. In that group, there was a 53% reduction in Candida colonization with statins, said Dr. Spanakis of Massachusetts General Hospital, Boston.
Dr. Spanakis said he had no financial disclosures. His coauthor, Dr. Eleftherios Mylonakis, has received research support from Astellas Pharma US Inc., and was a member of the speakers bureau for Pfizer Inc.
BOSTON — Statin therapy was associated with a significantly reduced risk for Candida colonization or infection in patients with type 2 diabetes who were undergoing gastrointestinal tract surgery.
Of the total 1,019 patients who underwent the surgery between January 1, 2001 and May 1, 2008, 48% (493) received statin therapy and 52% (526) did not. Those with statin exposure were older (67.8 vs. 64.9 years, respectively), and had a higher modified Charleson comorbidity index, Dr. Ilias Spanakis said.
A total of 139 patients developed Candida colonization or infection. After adjustment for major confounders, statin use was associated with a statistically significant 40% reduction in the development of Candida colonization or infection (odds ratio, 0.60).
Statins were associated with reduced risk of Candida colonization or infection regardless of Charleson score, although there was a greater apparent benefit of statins in those with scores of 2 or higher, indicating more comorbidity. In that group, there was a 53% reduction in Candida colonization with statins, said Dr. Spanakis of Massachusetts General Hospital, Boston.
Dr. Spanakis said he had no financial disclosures. His coauthor, Dr. Eleftherios Mylonakis, has received research support from Astellas Pharma US Inc., and was a member of the speakers bureau for Pfizer Inc.
BOSTON — Statin therapy was associated with a significantly reduced risk for Candida colonization or infection in patients with type 2 diabetes who were undergoing gastrointestinal tract surgery.
Of the total 1,019 patients who underwent the surgery between January 1, 2001 and May 1, 2008, 48% (493) received statin therapy and 52% (526) did not. Those with statin exposure were older (67.8 vs. 64.9 years, respectively), and had a higher modified Charleson comorbidity index, Dr. Ilias Spanakis said.
A total of 139 patients developed Candida colonization or infection. After adjustment for major confounders, statin use was associated with a statistically significant 40% reduction in the development of Candida colonization or infection (odds ratio, 0.60).
Statins were associated with reduced risk of Candida colonization or infection regardless of Charleson score, although there was a greater apparent benefit of statins in those with scores of 2 or higher, indicating more comorbidity. In that group, there was a 53% reduction in Candida colonization with statins, said Dr. Spanakis of Massachusetts General Hospital, Boston.
Dr. Spanakis said he had no financial disclosures. His coauthor, Dr. Eleftherios Mylonakis, has received research support from Astellas Pharma US Inc., and was a member of the speakers bureau for Pfizer Inc.